Clinical Trial Update: Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228-030) [Phase 2]

View source ↗

Summary

Phase 2 pediatric study of letermovir for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• PREVYMIS (letermovir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Cytomegalovirus (CMV) Infection | Phase 2 | Status: COMPLETED | Results posted: 2024-01-30